CL2012003178A1 - Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. - Google Patents
Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia.Info
- Publication number
- CL2012003178A1 CL2012003178A1 CL2012003178A CL2012003178A CL2012003178A1 CL 2012003178 A1 CL2012003178 A1 CL 2012003178A1 CL 2012003178 A CL2012003178 A CL 2012003178A CL 2012003178 A CL2012003178 A CL 2012003178A CL 2012003178 A1 CL2012003178 A1 CL 2012003178A1
- Authority
- CL
- Chile
- Prior art keywords
- psychosis
- dementia
- parkinson
- depression
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmacéuticamente aceptables, como inhibidores de PDE10; composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de Parkinson, depresión, trastornos del humor y demencia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33452510P | 2010-05-13 | 2010-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012003178A1 true CL2012003178A1 (es) | 2013-07-05 |
Family
ID=44278966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012003178A CL2012003178A1 (es) | 2010-05-13 | 2012-11-13 | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. |
Country Status (25)
Country | Link |
---|---|
US (3) | US8957073B2 (es) |
EP (1) | EP2569300A1 (es) |
JP (1) | JP5702855B2 (es) |
KR (1) | KR101564806B1 (es) |
CN (1) | CN103221404B (es) |
AR (1) | AR081627A1 (es) |
AU (1) | AU2011253057B2 (es) |
BR (1) | BR112012029026A2 (es) |
CA (1) | CA2798490A1 (es) |
CL (1) | CL2012003178A1 (es) |
CO (1) | CO6630189A2 (es) |
CR (1) | CR20120635A (es) |
EA (1) | EA201291236A1 (es) |
IL (1) | IL222898A (es) |
MA (1) | MA34300B1 (es) |
MX (1) | MX2012013130A (es) |
NZ (1) | NZ603876A (es) |
PE (1) | PE20130576A1 (es) |
SG (1) | SG185515A1 (es) |
TN (1) | TN2012000530A1 (es) |
TW (1) | TW201206902A (es) |
UA (1) | UA109438C2 (es) |
UY (1) | UY33382A (es) |
WO (1) | WO2011143365A1 (es) |
ZA (1) | ZA201208510B (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20130576A1 (es) * | 2010-05-13 | 2013-05-19 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 |
JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Pde10阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
JP2013526524A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Pde10阻害剤としてのアリールおよびヘテロアリール窒素ヘテロ環式化合物 |
AU2011253058A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
RU2013142364A (ru) | 2011-02-18 | 2015-03-27 | Аллерган, Инк. | Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) |
SG10201801668WA (en) | 2011-06-10 | 2018-03-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
US8623860B2 (en) * | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
TW201348231A (zh) * | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
CA2872989A1 (en) * | 2012-05-09 | 2013-11-14 | Zoetis Llc | Azetidine derivatives as antiparasitic agents |
UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
WO2014089364A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc | Histone demethylase inhibitors |
US20150374687A1 (en) * | 2013-02-07 | 2015-12-31 | Merck Patent Gmbh | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
CN106164066B (zh) | 2014-02-13 | 2020-01-17 | 因赛特公司 | 作为lsd1抑制剂的环丙胺 |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3105216B1 (en) * | 2014-02-14 | 2018-10-10 | Takeda Pharmaceutical Company Limited | Pyrazine modulators of gpr6 |
CN104016909B (zh) * | 2014-04-03 | 2016-04-20 | 定陶县友帮化工有限公司 | 一种2-氨基-3-溴-5-氯吡啶的合成方法 |
CN104016911A (zh) * | 2014-04-03 | 2014-09-03 | 定陶县友帮化工有限公司 | 一种2-氨基-3,5-二溴吡啶的合成方法 |
NZ726874A (en) | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
AU2015308350B2 (en) | 2014-08-29 | 2020-03-05 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US9855249B2 (en) | 2014-10-02 | 2018-01-02 | Flatley Discovery Lab, Llc | Isoxazole compounds and methods for the treatment of cystic fibrosis |
ES2757948T3 (es) | 2015-04-03 | 2020-04-30 | Incyte Corp | Compuestos heterocíclicos como inhibidores LSD1 |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
KR102664509B1 (ko) | 2016-04-22 | 2024-05-10 | 인사이트 코포레이션 | Lsd1 억제제의 제제 |
WO2017205425A1 (en) * | 2016-05-24 | 2017-11-30 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
DK3555064T5 (da) * | 2016-12-16 | 2023-05-01 | Pfizer | GLP-1 receptoragonister og anvendelser deraf |
DK3571193T3 (da) | 2017-01-23 | 2022-01-17 | Cadent Therapeutics Inc | Potassium Channel Modulators |
CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基)吡啶二盐酸盐的合成方法 |
EP3700935A4 (en) | 2017-10-25 | 2021-08-04 | University Of South Florida | INGREDIENT-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM |
SI3700902T1 (sl) | 2017-10-27 | 2023-10-30 | Boehringer Ingelheim International Gmbh | Inhibitorji trpc6 |
CN109956931B (zh) * | 2017-12-26 | 2021-07-16 | 迈第康(上海)生物医药科技有限公司 | 四氢吡咯类化合物、其制备方法、药物组合物及用途 |
LT3762368T (lt) | 2018-03-08 | 2022-06-10 | Incyte Corporation | Aminopirazindiolio junginiai, kaip pi3k-γ inhibitoriai |
US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
HUE061888T2 (hu) * | 2018-06-15 | 2023-08-28 | Pfizer | GLP-1 receptor agonisták és alkalmazásaik |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
ES2958917T3 (es) | 2018-10-02 | 2024-02-16 | Syngenta Participations Ag | Compuestos de benceno-amida y azina-amida con actividad plaguicida |
CA3116339A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
US20220024901A1 (en) * | 2018-11-22 | 2022-01-27 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
WO2020110964A1 (ja) | 2018-11-26 | 2020-06-04 | 京セラ株式会社 | ガスノズルおよびガスノズルの製造方法ならびにプラズマ処理装置 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
TW202102489A (zh) | 2019-03-29 | 2021-01-16 | 瑞士商先正達農作物保護公司 | 殺有害生物活性之二𠯤-醯胺化合物 |
KR20210149113A (ko) | 2019-04-05 | 2021-12-08 | 신젠타 크롭 프로텍션 아게 | 살충 활성 디아진-아미드 화합물 |
MX2021012290A (es) | 2019-04-11 | 2021-11-12 | Syngenta Crop Protection Ag | Compuestos de diazina-amida activos como pesticidas. |
JP2022527607A (ja) * | 2019-04-12 | 2022-06-02 | キル・レガー・セラピューティクス・インコーポレーテッド | Glp-1rアゴニスト及びその使用 |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
WO2021037614A1 (en) | 2019-08-23 | 2021-03-04 | Syngenta Crop Protection Ag | Pesticidally active pyrazine-amide compounds |
WO2021050913A1 (en) * | 2019-09-12 | 2021-03-18 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
KR102344561B1 (ko) * | 2019-11-15 | 2021-12-29 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
US20230203021A1 (en) * | 2020-03-18 | 2023-06-29 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
JP2023551195A (ja) * | 2020-11-19 | 2023-12-07 | セレシン・インコーポレーテッド | 放射性医薬ケトン、ならびにアルツハイマー病、認知機能障害、および他の変化した脳代謝の状態における二重トレーサーイメージング |
EP4352050A1 (en) | 2021-06-09 | 2024-04-17 | Syngenta Crop Protection AG | Pesticidally active diazine-amide compounds |
JP2024522718A (ja) * | 2021-06-16 | 2024-06-21 | セルジーン コーポレーション | 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物 |
KR20240024935A (ko) | 2021-06-18 | 2024-02-26 | 알리고스 테라퓨틱스 인코포레이티드 | Pd-l1을 표적화하기 위한 방법 및 조성물 |
WO2024084447A2 (en) * | 2022-10-20 | 2024-04-25 | Dong-A St Co., Ltd. | Azetidinyl benzoxazole compounds and their use as mer and axl inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
HN2002000266A (es) | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
SI2527315T1 (sl) * | 2002-05-31 | 2014-06-30 | Proteotech Inc., | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen |
CA2501539A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde10a阻害剤を用いる糖尿病および関連障害の処置方法 |
GB0325287D0 (en) * | 2003-10-29 | 2003-12-03 | Merck Sharp & Dohme | Therapeutic agents |
KR100907354B1 (ko) * | 2004-05-18 | 2009-07-10 | 쉐링 코포레이션 | Pde4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸 |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
US20070072908A1 (en) | 2005-06-08 | 2007-03-29 | Japan Tobacco Inc. | Heterocyclic compounds |
US7709501B2 (en) * | 2005-12-23 | 2010-05-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
JP2009524637A (ja) * | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
CN101952286A (zh) | 2007-12-21 | 2011-01-19 | 阿斯利康(瑞典)有限公司 | 用于治疗和雄激素受体有关的病症的双环衍生物 |
CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
BRPI1012870B8 (pt) | 2009-05-12 | 2021-05-25 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostericos positivos de receptores de mglur2 e composição farmacêutica |
JP5696856B2 (ja) | 2009-09-03 | 2015-04-08 | バイオエナジェニックス | Paskの阻害用複素環式化合物 |
US8802679B2 (en) * | 2009-09-16 | 2014-08-12 | Astellas Pharma Inc. | Glycine compound |
JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Pde10阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
JP2013526524A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Pde10阻害剤としてのアリールおよびヘテロアリール窒素ヘテロ環式化合物 |
AU2011253058A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
PE20130576A1 (es) * | 2010-05-13 | 2013-05-19 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 |
UY34858A (es) | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
-
2011
- 2011-05-11 PE PE2012002159A patent/PE20130576A1/es not_active Application Discontinuation
- 2011-05-11 US US13/105,860 patent/US8957073B2/en active Active
- 2011-05-11 MX MX2012013130A patent/MX2012013130A/es unknown
- 2011-05-11 WO PCT/US2011/036148 patent/WO2011143365A1/en active Application Filing
- 2011-05-11 CN CN201180034741.6A patent/CN103221404B/zh not_active Expired - Fee Related
- 2011-05-11 EA EA201291236A patent/EA201291236A1/ru unknown
- 2011-05-11 NZ NZ603876A patent/NZ603876A/en not_active IP Right Cessation
- 2011-05-11 JP JP2013510285A patent/JP5702855B2/ja not_active Expired - Fee Related
- 2011-05-11 KR KR1020127032541A patent/KR101564806B1/ko not_active IP Right Cessation
- 2011-05-11 EP EP11721618A patent/EP2569300A1/en not_active Withdrawn
- 2011-05-11 CA CA2798490A patent/CA2798490A1/en not_active Abandoned
- 2011-05-11 AU AU2011253057A patent/AU2011253057B2/en not_active Ceased
- 2011-05-11 SG SG2012082939A patent/SG185515A1/en unknown
- 2011-05-11 MA MA35440A patent/MA34300B1/fr unknown
- 2011-05-11 BR BR112012029026A patent/BR112012029026A2/pt not_active Application Discontinuation
- 2011-05-12 UY UY0001033382A patent/UY33382A/es not_active Application Discontinuation
- 2011-05-13 TW TW100116952A patent/TW201206902A/zh unknown
- 2011-05-13 AR ARP110101668A patent/AR081627A1/es unknown
- 2011-11-05 UA UAA201214182A patent/UA109438C2/uk unknown
-
2012
- 2012-11-06 IL IL222898A patent/IL222898A/en not_active IP Right Cessation
- 2012-11-07 TN TNP2012000530A patent/TN2012000530A1/en unknown
- 2012-11-12 ZA ZA2012/08510A patent/ZA201208510B/en unknown
- 2012-11-13 CL CL2012003178A patent/CL2012003178A1/es unknown
- 2012-11-15 CO CO12207172A patent/CO6630189A2/es active IP Right Grant
- 2012-12-13 CR CR20120635A patent/CR20120635A/es unknown
-
2014
- 2014-04-01 US US14/242,432 patent/US20140213572A1/en not_active Abandoned
-
2015
- 2015-12-17 US US14/973,491 patent/US9718803B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CO6630189A2 (es) | 2013-03-01 |
AR081627A1 (es) | 2012-10-10 |
JP5702855B2 (ja) | 2015-04-15 |
TN2012000530A1 (en) | 2014-04-01 |
UA109438C2 (uk) | 2015-08-25 |
PE20130576A1 (es) | 2013-05-19 |
US20140213572A1 (en) | 2014-07-31 |
CR20120635A (es) | 2013-01-30 |
WO2011143365A1 (en) | 2011-11-17 |
UY33382A (es) | 2011-10-31 |
CA2798490A1 (en) | 2011-11-17 |
EA201291236A1 (ru) | 2013-11-29 |
JP2013526536A (ja) | 2013-06-24 |
TW201206902A (en) | 2012-02-16 |
IL222898A0 (en) | 2012-12-31 |
ZA201208510B (en) | 2017-11-29 |
MX2012013130A (es) | 2013-04-11 |
NZ603876A (en) | 2015-02-27 |
SG185515A1 (en) | 2012-12-28 |
CN103221404B (zh) | 2015-12-16 |
US20160102075A1 (en) | 2016-04-14 |
KR101564806B1 (ko) | 2015-10-30 |
KR20130065666A (ko) | 2013-06-19 |
BR112012029026A2 (pt) | 2016-08-02 |
US8957073B2 (en) | 2015-02-17 |
AU2011253057A1 (en) | 2012-11-29 |
MA34300B1 (fr) | 2013-06-01 |
IL222898A (en) | 2015-11-30 |
US20110306587A1 (en) | 2011-12-15 |
AU2011253057B2 (en) | 2014-11-20 |
CN103221404A (zh) | 2013-07-24 |
US9718803B2 (en) | 2017-08-01 |
EP2569300A1 (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012003178A1 (es) | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2016001895A1 (es) | Compuestos | |
ECSP16071151A (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
GT201400196A (es) | Compuestos de heterociclilo | |
BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
UY36153A (es) | ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos? | |
CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
PE20151070A1 (es) | Inhibidores de la tirosina - quinasa de bruton | |
UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
CL2012001073A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias. | |
UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
CL2009001212A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras. | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. |